- 49 Downloads
l-Carnitine 1 occurs naturally as an essential cofactor of fatty acid metabolism which is synthesised endogenously or obtained from dietary sources. In patients with primary carnitine deficiencies, which may be life-threatening, and some secondary deficiencies such as organic acidurias, the exogenously administered compound is clearly beneficial: by abolishing hypotonia, motor skills are improved, as are muscle weakness and wasting. In preliminary clinical trials in patients with ischaemic cardiac disease, therapy with l-carnitine has shown beneficial effects on myocardial function and metabolism and has improved exercise tolerance in patients with angina pectoris — findings which require further substantiation in larger controlled studies. Moreover, while some interesting evidence suggests that l-carnitine may find potential use in such diverse conditions as carnitine deficiencies secondary to prolonged total parenteral nutrition supplementation or chronic haemodialysis, hyperlipidaemias and the prevention of toxicity induced by anthracyclines and valproate, such findings must be regarded as preliminary. Exogenously administered l-carnitinine is very well tolerated.
Thus, while its role in primary deficiencies is established, with its profile of negligible toxicity l-carnitine is worthy of further investigation to more clearly define its therapeutic applications in a variety of conditions which may be indirectly related to alterations in fatty acid metabolism.
Role of l-Carnitine in Fatty Acid Metabolism
l-Carnitine is a cofactor of several enzymes (carnitine translocase, acylcarnitine transferases I and II) necessary for the transformation of free long chain fatty acids to acylcarnitines, and their transport into the mitochondrial matrix. β-Oxidation of these compounds precedes their entry into the Krebs cycle, where energy production occurs. In the absence of l-carnitine, the accumulation of free fatty acids in the cytoplasm produces a toxic effect on the cell, and an energy deficit arises from the unavailability of fatty acids within the mitochondria.
The pharmacokinetic properties of exogenously administered l-carnitine have not been thoroughly described. Peak plasma concentrations of free carnitine of 48.5 and 69 µmol/L have been attained 3.5 to 5 hours following single oral 500mg and 2g doses, respectively. l-Carnitine is actively transported into tissues via a saturable system, although passive diffusion also occurs. The volume of distribution is about 26% of bodyweight. The compound is likely not metabolised in humans (other than by partial conversion to acylcarnitine esters) and thus is eliminated via the kidneys. The portion of a dose of l-carnitine excreted in the urine within 24 hours varies depending on the route of administration. Thus, following an intravenous dose 80% has been recovered, in contrast to 7% of a dose recovered within 24 hours following an oral dose. Faecal elimination accounts for less than 2% of a dose. In healthy volunteers, the half-life of l-carnitine ranges from 2 to 15 hours.
Use in Patients with Ischaemic Cardiac Disease
The rationale for the use of l-carnitine in patients with ischaemic heart disease relates to the premise that increased lactate production and decreased energy output of cardiac muscle in such patients result in part from decreased l-carnitine concentrations in heart muscle, which has been demonstrated at necropsy in the necrotic area and the infarct border tissue of patients who died of myocardial infarction. In single dose studies in patients with ischaemic heart disease, l-carnitine 40 or 140 mg/kg intravenously or 1g daily orally, and dl-carnitine 20 or 40 mg/kg intravenously, decreased lactate production and increased the free fatty acid extraction ratio in the myocardium. Orally administered l-carnitine decreased the release of creatine kinase isoenzyme MB fraction in patients with acute myocardial infarction.
In patients with moderately impaired left ventricular function, intravenously administered l-carnitine 40 mg/kg exerted a positive inotropic effect as evidenced by a decrease in the left ventricular diastolic pressure and the pre-ejection period/left ventricular ejection time ratio. These effects were confirmed in patients treated with l-carnitine 2g intravenously daily for 10 days.
Preliminary trials in patients with chronic stable angina pectoris have indicated that orally administered l-carnitine 900 to 2000mg daily improved exercise tolerance, lessened the extent of ST segment depression, decreased the frequency of anginal attacks and reduced glyceryl trinitrate (nitroglycerin) consumption. These findings are supported by the results of an open multicentre study in more than 1000 patients with angina pectoris, which demonstrated that a reduction was obtained in the consumption of traditional antianginal drug therapies and the frequency of anginal attacks during the 12-month period of supplementation with oral l-carnitine 2g daily.
While some interesting evidence suggests that l-carnitine may be of benefit in the treatment of patients with acute myocardial infarction or arrhythmias, its role as an adjuvant in therapy of these conditions awaits definition in further studies.
Effects of l-Carnitine in Primary Deficiency
Concentrations of l-carnitine are below normal in the plasma, liver and muscle of patients with systemic carnitine deficiencies (SCD), and in the muscle of those with the myopathic form, possibly because of impaired transport or biosynthesis of l-carnitine. Replacement therapy with the drug in regimens of up to 4g daily reverses such clinical symptoms as severe muscular weakness, hypoglycaemia and intellectual retardation seen in patients more severely afflicted with SCD, and can be life-saving in some instances. Similarly, in patients with the less debilitating myopathic deficiency there has been objective and subjective evidence of improved muscle strength within 1 week of the commencement of l-carnitine therapy.
Use in Secondary Deficiencies
l-Carnitine has been shown to be of benefit in children with defects of intermediary metabolism (organic acidurias) who display impaired motor skills and low plasma concentrations of carnitine.
There is some evidence to indicate that the elevated plasma concentrations of triglycerides and total cholesterol in patients undergoing chronic intermittent haemodialysis can be decreased by l-carnitine supplementation, whether administered orally, intravenously or added to the dialysate. However, results of those studies that have included a placebo control have varied, and in view of the paradoxical increase in plasma triglycerides associated with high oral doses of l-carnitine (3g daily) in 1 trial, further studies are required to determine the optimum dose in these patients.
A few blind and non-blind studies in small numbers of patients with symptoms of the ‘post-dialysis syndrome’ have demonstrated symptomatic improvement after 2 or more months’ treatment with l-carnitine 990 to 2000mg daily, although objective measurements in one study did not alter significantly.
The addition of l-carnitine to total parenteral nutrition regimens in neonates has increased plasma concentrations of total and free carnitine which are lower than in infants fed by enterai methods. Some evidence indicates that carnitine supplementation results in better metabolism of intravenously administered fat emulsion, especially in premature infants.
A few uncontrolled studies in patients who had received anthracycline therapy in cumulative doses of less than 500 mg/m2, suggest that orally or intravenously administered l-carnitine may decrease the severity of cardiotoxicity associated with daunorubicin or doxorubicin administration.
l-Carnitine is very well tolerated; at doses of up to 15g daily no side effects have occurred other than infrequent diarrhoea, gastralgia and nausea. A symptom similar to myasthenia gravis which has been reported with the administration of dl-carnitine has not been seen with l-carnitine therapy.
The usual dose of l-carnitine in adults with primary or secondary carnitine deficiencies or ischaemic cardiomyopathies is 1g given orally or parenterally 1 to 3 times daily. Children should receive 50 to 100 mg/kg daily in 2 to 3 divided doses.
Unable to display preview. Download preview PDF.
- Adamo S, Tonon M, Carrara M, Sartori G, Ghidini O. Effect of carnitine on serum triglycerides in alcoholism: a double-blind placebo controlled trial. In Borum (Ed.) Clinical aspects of human carnitine deficiency, p.244, Pergamon Press, New York, 1986Google Scholar
- Albertazzi A, Capelli P, Di Paolo B, Pola P, Tondi P, et al. Endocrine-metabolic effects of l-carnitine in patients on regular dialysis treatment. Proceedings of the EDTA 19: 302–307, 1982Google Scholar
- Angelini C, Vergani L, Costa L, Martinuzzi A, Dünner E, et al. Clinical study of efficacy of l-carnitine and metabolic observations in exercise physiology. In Borum (Ed.) Clinical aspects of human carnitine deficiency, p. 38, Pergamon Press, New York, 1986Google Scholar
- Ashbrook DW. Carnitine supplementation in human carnitine deficiency. In Borum (Eds) Clinical aspects of human carnitine deficiency, pp. 120–134, Pergamon Press, New York, 1986Google Scholar
- Aubia J, Masramon J, Lhoveras J, Llorach M, Andolz P. Carnitine in haemodialysis patients. Lancet 2: 1028, 1980Google Scholar
- Bach AC, Schirardin H, Sihr M-O, Storck D. Free and total carnitine in human serum after oral ingestion of l-carnitine. Diabete and Metabolisme (Paris) 9: 121–124, 1983Google Scholar
- Balogh D, Hackl JM, Legenstein E, Musil HE. Erfahrungen mit 1-camitin in der post-aggressions phase. Infusion therapie 13: 204–208, 1986Google Scholar
- Bellinghieri G, Savica V, Mallama A, Di Stefano C, Consolo F, et al. Correlation between increased serum and tissue l-carnitine levels and improved muscle symptoms in hemodialyzed physiokinesiotherapy in chronic respiratory insufficiency. Clinical Trials Journal 4: 353–360, 1985Google Scholar
- Dal Negro R, Zoccatelli O, Pomari G, Turco P. Changes in physical performance of untrained volunteers: effects of l-carnitine. Clinical Trials Journal 23: 242–248, 1986bGoogle Scholar
- Del-Valle JA, Martinez-Pardo M, Ludena C, Camarero C, Del-Olmo R, et al. A new patient with dicarboxylic aciduria presenting as Reye’s syndrome. 21st Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Lyon, September 6–9, 1983Google Scholar
- Di Donato S, Rimoldi M, Garavaglia B, Uziel G. Propionylcarnitine excretion in propionic acid and methylmalonic acidurias: a cause of carnitine deficiency. Clinica Chimica Acta 139: 13–21, 1984bGoogle Scholar
- Di Marco V, Ginardi V, Dell’aira E, Abbate M, Costanza MG, et al. La camitina nel trattamento dei crampi muscolari nei pazienti in emodialisi periodica. Policlinico Sez. Med. 89: 104–110, 1982Google Scholar
- Donatelli M, Terrizzi C, Zummo G, Russo V, Bucalo ML, et al. Effects of l-carnitine on chronic anaemia and erythrocyte adenosine triphosphate (ATP) concentration in haemodialysed patients. Current Therapeutic Research, in press, 1987Google Scholar
- Fagher B, Cederblad G, Eriksson M, Monti M, Moritz U, et al. l-Carnitine and haemodialysis: double-blind study on muscle function and metabolism and peripheral nerve function. Scandanavian Journal of Clinical and Laboratory Investigation 45: 169–178, 1985bGoogle Scholar
- Fernandez C, La Menza B, Pola P. Trials clinici difase IV e di farmacovigilanza-nuove ipotesi metodologiche-il terzo trial Ance. Journal of the American Medical Association (Italian Edition) 2: Number 9, 1985Google Scholar
- Ferrari R, Cucchini F, DiLisa F, Raddino R, Bolognesi R, et al. The effect of l-carnitine (camitene) on myocardial metabolism of patients with coronary artery disease. Clinical Trials Journal 21: 40–58, 1984Google Scholar
- Furitano G, Patema S, Perricone R, Barbarino C, Palumbo FP, et al. Polygraphic evaluation of effects of carnitine in patients on adriamycin treatment. Drugs Under Experimental and Clinical Research 10: 107–111, 1984Google Scholar
- Garzya G, Amico RM. Comparative study on the activity of racemic and laevorotatory carnitine in stable angina pectoris. International Journal of Tissue Reactions 2: 175–180, 1980Google Scholar
- Geber N, Dickinson RG, Harland RC, Lynn RK, Houghton D, et al. Reye-like syndrome associated with valproic acid. Journal of Pediatrics 95: 142, 1979Google Scholar
- Gilly R, Carrier H, Lamit J. Myopathie congénitale avec surcharge de la fibre musculaire en lipids et glycogene et déficit partiel en carnitine. Annals de Pédiatre 27: 319–324, 1980Google Scholar
- Giordano MP, Corsi M, Roncarolo P, Falcone M, Gabasio C. Effect of l-carnitine on systolic time intervals in coronary artery disease. Current Therapeutic Research 33: 305–311, 1983Google Scholar
- Kerr P, Shurin S, Tsemg K-Y, Hoppel C. Metabolic effects of treatment of systemic carnitine deficiency. Pediatric Research 15: 633, 1981Google Scholar
- Kudoh Y, Shoji T, Oimatsu H, Kikuchi K, Iimura O, et al. Plasma l-carnitine in patients with chronic hemodialysis — pharmacokinetics of l-carnitine and its replacement therapy in these patients. Nippon Jimzo Gakki Shi 26: 57–64, 1984Google Scholar
- Labonia WD, Morelli Jr OH, Gimenez ML, Freuler PV, Morelli OH. Effects of l-carnitine on sodium transport in erythrocytes from dialyzed uremic patients. VI Argentinian Congress of Nephrology, Buenos Aires, November 12–15, 1986Google Scholar
- Leschke M, Rumpf W, Eisenhauer T, Fuchs C, Becker K, et al. Quantitative assessment of carnitine loss during hemodialysis and hemofiltration. Kidney International 24(Suppl. 16): S143–S146, 1983Google Scholar
- Liedtke AJ. Metabolism of the ischemic heart: alterations in fatty acid intermediates and role of carnitine. In Kaiser et al. (Eds) Carnitine — its role in lung and heart disorders, pp. 100–111, Karger, Munich, 1987Google Scholar
- Logue RB. Metabolic regulation and myocardial function. In Logue et al. (Eds) The heart, 6th ed., pp.91–94, McGraw-Hill, New York, 1985aGoogle Scholar
- Logue RB. Metabolic regulation and myocardial function. In Logue et al. (Eds) The heart, 6th ed., pp.568–569, McGraw-Hill, New York, 1985bGoogle Scholar
- Logue RB. Metabolic regulation and myocardial function. In Logue et al. (Eds) The heart, 6th ed., pp.653–654, McGraw-Hill, New York, 1985cGoogle Scholar
- Maebashi M, Kawamura N, Sato M, Yoshinaga K, Suzuki M. Urinary excretion of carnitine in man. Journal of Laboratory and Clinical Medicine 87: 760–766, 1976Google Scholar
- Marconi C, Sassi G, Carpinelli A, Cerretelli P. Effects of l-carnitine loading on the aerobic and anaerobic performance of endurance athletes. European Journal of Applied Physiology 54: 131–135, 1985Google Scholar
- Markesberry WR, McQuillen MP, Protopia PG, Harrison AR, Engel AG. Muscle carnitine deficiency. Archives of Neurology 31: 320–324, 1974Google Scholar
- Martin P, Carrier H, Renoud JF, Kullmann B, Delpont E, et al. Un cas de myopathie avec déficit en carnitine. Revue Neurologique (Paris) 142: 625–634, 1986Google Scholar
- Mioli V, Tarchini R, Boggi R. Use of dl- and l-carnitine in uraemic patients on intermittent haemodialysis. International Journal of Clinical Pharmacology Research 2: 143–148, 1982Google Scholar
- Neri B, Torcia MG, Comparini T, Guidi S, Miliani A, et al. Creatin kinase-MB: a non-invasive test monitoring acute adriamycin and daunomycin cardiotoxicity. Journal of Experimental and Clinical Cancer Research 2: 41–45, 1983aGoogle Scholar
- Neri B, Comparini T, Miliani A, Torcia M. Protective effects of l-carnitine (camitene) on acute adriamycin and daunomycin cardiotoxicity in cancer patients. Clinical Trials Journal 20: 98–103, 1983bGoogle Scholar
- Nilsson-Ehle P, Cederblad G, Fagher B, Monti M, Thysell H. Plasma lipoproteins, liver function and glucose metabolism in haemodialysis patients: lack of effect of 1-carnitine supplementation. Scandanavian Journal of Clinical and Laboratory Investigation 45: 179–184, 1985Google Scholar
- Noto R, Maugeri A, Grasso R, Sfogliano L. Free fatty acids and carnitine in patients with liver disease. Current Therapeutic Research 40: 35–39, 1986Google Scholar
- Pelligrini G, Scarlato G, Moggio M. A hereditary case of lipid storage myopathy with carnitine deficiency. Journal of Neurology 223: 73–84, 1980Google Scholar
- Pola P, Savi L, Grilli M, Flore R, Serricchio M. Carnitine in the therapy of dyslipidemie patients. Current Therapeutic Research 27: 208–216, 1979Google Scholar
- Pola P, Tondi P, Dal Lago A, Sericchio M, Flore R. Statistical evaluation of long-term l-carnitine therapy in hyperlipoproteinaemias. Drugs under Experimental and Clinical Research 12: 925–935, 1983Google Scholar
- Rebuzzi AG, Schiavoni G, Amico CM, Montenero AS, Meo F, et al. Beneficial effects of l-carnitine in the reduction of the necrotic area in acute myocardial infarction. Drugs Under Experimental and Clinical Research 10: 219–223, 1984Google Scholar
- Reforzo G, De Andreis Bessone PL, Rebaudo F, Tibaldi M. Evaluation of the effects of high doses of l-carnitine on the myocardial lactate balance during pacing-induced ischemia in ageing subjects. Current Therapeutic Research, in press, 1986Google Scholar
- Rocchi L, Feola I, Calvani M, D’ladio S, Alfarone C, Frascarelli M. Effects of carnitine administration in patients with chronic renal failure undergoing periodic dialysis, evaluated by computerized electromyography. Drugs Under Experimental and Clinical Research 12: 707–711, 1986PubMedGoogle Scholar
- Rodriguez-Segade S, Alonso de la Peña C, Paz JM, Novoa D, et al. Carnitine deficiency in haemodialysed patients. Clinica Chimica Acta 159: 249–256, 1986Google Scholar
- Sawicka E, Ketelsen U-P, Petrykowski W, Schmidt-Sommerfeld E. Mitochondrial abnormalities in systemic carnitine deficiency before and after successful treatment with l-carnitine. Fifth International Congress on Neuromuscular Diseases, Marseille, September, 1982Google Scholar
- Scarlato G, Pellegrini G, Moggio M, Meola G, Frattola L. Carnitine deficiency and lipid storage myopathy in three patients: analysis of some differential features. Perspectives in Inherited Metabolic Diseases 3: 109–128, 1979Google Scholar
- Schiavoni G, Pennestri F, Mongiardo R, Mazzari M, Manzoli V. Cardiodynamic effects of l-carnitine in ischaemic cardiopathy. Drugs Under Experimental and Clinical Research 9: 171–185, 1983Google Scholar
- Schmidt-Sommerfeld E, Penn D, Sodha RJ, Prögler M, Schneider H. Transfer and metabolism of carnitine and carnitine esters in the in vitro perfused placenta. Contraception Gynecology and Obstetrics 13: 141–143, 1985Google Scholar
- Sciveres G. Esperienza con 1-camitina nel trattamento della angina stabile da sforzo. Archivio di Medicina Interna 36: 61–66, 1984Google Scholar
- Sugimoto T, Nishida N, Woo M, Takeuchi T, Yasuhara A, et al. Serum and urinary carnitine and organic acids in Reye syndrome and Reye-like syndrome. Brain & Development 8: 257–261, 1986Google Scholar
- Suzuki M, Kanaya M, Muramatsu S, Takahashi T. Effects of carnitine administration, fasting, and exercise on urinary carnitine excretion in man. Journal of Nutritional Science and Vitaminology 22: 169–174, 1976Google Scholar
- Trovato GM, Ginardi V, Di Marco V, Dell’aira A, Corsi M. Longterm l-carnitine treatment of chronic anaemia of patients with end-stage renal failure. Current Therapeutic Research 31: 1042–1049, 1982Google Scholar
- Vacha GM, Corsi M, Giorcelli G, D’iddio S, Maccari F. Serum and muscle l-carnitine levels in hemodialyzed patients during and after long-term l-carnitine treatment. Current Therapeutic Research 37: 505–516, 1985Google Scholar
- Vergani L, Bertoli M, Ruffatti A, Romagnoli GF, Angelini C. Treatment with l-carnitine in hemodialysis patients. Abstract no. 168, Third International Congress on Nutrition and Metabolism in Renal Disease, Marseille, September 1–4, 1982Google Scholar